Novartis will close the plant and transfer some operations to a Sandoz facility in North Carolina by late 2019. Novartis is Sandoz’s parent company.
The drug company will also discontinue or divest certain drug products to stay competitive in the U.S. drug market.
“The products that are being discontinued are oral generics that treat a variety of conditions in cardiology, central nervous system, endocrinology, respiratory and pain,” a Novartis spokesman told Reuters Thursday.
More articles on supply chain:
Survey: 5 attributes providers want when purchasing medical devices
Study: Cancer drug costs increase 25% in 8 years
UnitedHealth not concerned by possibility of Amazon entering drug business
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.